09/09/2025 21:56
|
Science
LEXINGTON, Mass.--BUSINESS WIRE--
Agenus Inc. (Nasdaq: AGEN), a leader in immuno‑oncology, today announced its investigational combination botensilimab plus balstilimab (BOT/BAL) is now available...